Eli Lilly's Triple Agonist Retatrutide Shows Promise in Phase III Trial | Retatrutide News

Eli Lilly's Retatrutide, a 'triple G' agonist, showed promise in a Phase III trial but raised concerns due to adverse events. The trial underscores the ...
Clinical Trials · October 21, 2026